BAUSCH HEALTH IRELAND LIMITED et al v. GLENMARK PHARMACEUTICALS LIMITED
ASSERTIO THERAPEUTICS INC. and BAUSCH HEALTH IRELAND LIMITED |
GLENMARK PHARMACEUTICALS LIMITED |
1:2019cv12045 |
May 1, 2019 |
US District Court for the District of New Jersey |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. ยง 271 |
None |
Docket Report
This docket was last retrieved on May 1, 2019. A more recent docket listing may be available from PACER.
Document Text |
---|
Filing 3 Corporate Disclosure Statement by ASSERTIO THERAPEUTICS INC. identifying BlackRock, Inc. as Corporate Parent.. (DENI, WILLIAM) |
Filing 2 Corporate Disclosure Statement by BAUSCH HEALTH IRELAND LIMITED identifying Bausch Health Companies Inc. as Corporate Parent.. (DENI, WILLIAM) |
Filing 1 COMPLAINT against GLENMARK PHARMACEUTICALS LIMITED ( Filing and Admin fee $ 400 receipt number 0312-9633488), filed by BAUSCH HEALTH IRELAND LIMITED, ASSERTIO THERAPEUTICS INC.. (Attachments: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Civil Cover Sheet, #6 L. Civ. R. 11.2 Certification)(DENI, WILLIAM) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the New Jersey District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.